SCHEMBL8256016

SCHEMBL8256016

Cc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
DRD4 P21917 1/20 0.51
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2C19 P33261 1/20 0.48
ALPL P05186 1/20 0.48
PTBP1 P26599 1/20 0.48
MELK Q14680 6/20 0.47
CHEK1 O14757 2/20 0.47
PRKAB2 O43741 2/20 0.47
NUAK1 O60285 2/20 0.47
MAPK1 P28482 2/20 0.47
PRKAG1 P54619 2/20 0.47
PRKAA2 P54646 2/20 0.47
PRKAA1 Q13131 2/20 0.47
CAMKK2 Q96RR4 2/20 0.47
PRKAG3 Q9UGI9 2/20 0.47
PRKAG2 Q9UGJ0 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8354585 0.88 LMNA (0.61) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL436539 0.87 DRD4 (0.50) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL28504240 0.87 LMNA (0.52) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL7346138 0.86 CACNA2D1 (0.49) LMNACYP1A2CYP2C19ALPLPTBP1
SCHEMBL8355265 0.86 LMNA (0.60) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL12359040 0.86 DRD4 (0.67) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL22567606 0.85 DRD4 (0.55) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL30860308 0.85 MELK (0.54) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL20710180 0.84 DRD4 (0.51) LMNADRD4NPC1RAB9ASMN1; SMN2
SCHEMBL13227073 0.84 HPGD (0.51) LMNADRD4NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173699-B2 Compounds for the treatment of inflammatory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-08 US disclosed
US-20100190767-A1 Compounds for the treatment of inflammatory diseases ANDERSKEWITZ RALF 2010-07-29 US disclosed
EP-1727798-B1 NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INT (DE) 2008-10-29 EP disclosed
WO-2006114371-A1 NOVEL COMPOUNDS FOR TREATING INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-02 WO disclosed
WO-2005087726-A1 NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190767-A1 Compounds for the treatment of inflammatory diseases MALT1, IL1B, RORC LMNA 3209/4885DRD4 3606/4885NPC1 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.